|
| Thursday, 24 July 2014, 06:00 HKT/SGT | |
| |  | |
Source: Omnicare | |
|
|
|
Cincinnati, July 24, 2014 - (ACN Newswire) - Omnicare, Inc. (NYSE:OCR) reported today financial results for its second-quarter ended June 30, 2014.
Second-Quarter Highlights:
-- Net sales increase of 7.1% to $1.6 billion
-- Adjusted cash earnings per diluted share from continuing operations 7.1% higher to $0.91; GAAP earnings per diluted share of $0.21
-- Adjusted EBITDA from continuing operations of $176 million
-- Cash flows from continuing operations increase of 36.1% to $219 million
"We are pleased with our second-quarter results, which reflect consistent execution of our plan to drive long-term growth across our business," said Nitin Sahney, Omnicare's Chief Executive Officer. "We performed especially well within our Specialty Care Group, which generated double-digit increases in revenues and operating income. Moreover, we are encouraged by the development of our sales pipeline across our business, which we believe will benefit volumes as we exit 2014. With a disciplined focus on driving growth and optimizing our business operations and efficiencies, we believe we will continue to enhance value for our shareholders."
Second-Quarter Results
Financial results from continuing operations for the quarter ended June 30, 2014, as compared with the same prior-year period, were as follows:
-- Net sales were $1,611 million versus $1,503 million
-- Gross profit was $354 million as compared with $360 million
-- GAAP earnings per share was $0.58 versus $0.43
-- Adjusted cash earnings per diluted share was $0.91 versus $0.85
-- Adjusted EBITDA was $176 million versus $169 million
Cash flows from continuing operations for the quarter ended June 30, 2014 were $219 million versus $161 million in the comparable prior-year quarter.
Financial Position
Omnicare concluded the second-quarter of 2014 with no borrowings outstanding on its revolving credit facility, other than approximately $14 million in standby letters of credit, and $315 million in cash on its balance sheet.
In the second quarter, Omnicare repurchased 1.1 million shares for an aggregate amount of $65 million. As of June 30, 2014, the Company had approximately $340 million of availability under its current share repurchase authorization.
Also during the second quarter, Omnicare repurchased approximately $52 million in aggregate principal amount of its outstanding 3.75% Convertible Senior Subordinated Notes due 2025 (the "3.75% Notes due 2025") for approximately $134 million in cash. As of June 30, 2014, the remaining principal amount of the 3.75% Notes due 2025 outstanding was $80 million.
"During the second quarter, we achieved record quarterly operating cash flows, reflecting our methodical approach to working capital management," said Rocky Kraft, Omnicare's Chief Financial Officer. "We intend to remain focused on cash flow efficiency while ensuring we are opportunistic with respect to increasing returns through working capital strategies. We believe this balance will enable us to continue improving returns through a systematic approach to capital deployment."
Year-to-Date Results
Financial results from continuing operations for the six months ended June 30, 2014, as compared with the same prior-year period, were as follows:
-- Net sales were $3,182 million versus $2,962 million
-- Gross profit was $713 million as compared with $709 million
-- GAAP earnings per share was $1.17 versus $0.88
-- Adjusted cash earnings per diluted share was $1.82 versus $1.69
-- Adjusted EBITDA was $354 million versus $330 million
Cash flows from continuing operations for the six months ended June 30, 2014 were $390 million versus $267 million in the comparable prior-year quarter.
Segment Information
Financial results for the Long-Term Care Group for the second-quarter ended June 30, 2014 were as follows:
-- Net sales of $1,190 million were 2.7% higher than $1,159 million in the same prior-year period
-- Adjusted operating income of $160.0 million was in-line with the same prior-year period
Financial results for the Specialty Care Group for the second-quarter ended June 30, 2014 were as follows:
-- Net sales of $420 million were 22% higher than $343 million in the same prior-year period
-- Operating income of $31.1 million increased 15% from $27.1 million in the same prior-year period
To facilitate comparisons and to enhance the understanding of core operating performance, discussions in this news release include financial measures that are adjusted from the comparable amounts under GAAP to exclude the impact of the special items discussed elsewhere herein, and to present results on a continuing operations basis. For a detailed presentation of reconciling items and related definitions and components, please refer to the attached schedules or to reconciliation schedules posted at the Investor Relations section of Omnicare's website at http://ir.omnicare.com. Additionally, the Company will make supplemental slides available in the same section on its website today that will include the number of scripts dispensed and other information relevant to Omnicare's operations.
Special Items
The results for the second-quarters ended June 30, 2014 and 2013 include the impact of special items and cash EPS adjustments as follows:
----------------------------------------------------------------------
Three months ended Six months ended
June 30, June 30,
2014 2013 2014 2013
----------------------------------------------------------------------
A B A B A B A B
----------------------------------------------------------------------
Special Items Adj.
$15.9M $0.15 $25.2M $0.23 $30.2M $0.28 $45.3M $0.42
Cash EPS Adj.
$19.8M $0.19 $21.2M $0.19 $39.7M $0.37 $42.5M $0.39
----------------------------------------------------------------------
A: After-tax impact
B: Per diluted share
All special items and cash EPS adjustments have been described in further detail in the "Footnotes and Definitions to Financial Information" section elsewhere herein.
Outlook
Based upon its first half results, Omnicare updated its expectations for cash flows and reaffirmed other elements of its full-year guidance to reflect the following:
----------------------------------------------------------------------
Original Guidance Current Guidance
----------------------------------------------------------------------
Revenue $6.3B to $6.4B $6.3B to $6.4B
Adjusted cash earnings per diluted share (excluding special items)
$3.64 to $3.72 $3.64 to $3.72
Cash flows from operations (excluding settlement payments)
$475M to $550M $500M to $550M
----------------------------------------------------------------------
Webcast Today
Omnicare will hold a conference call to discuss its second-quarter 2014 financial results today, Wednesday, July 23, at 9:00 a.m. ET. A live webcast of the conference call and supplemental slides will be accessible from the Investor Relations section of Omnicare's website at http://ir.omnicare.com. An archived replay will be made available on the website following the conclusion of the conference call.
About Omnicare
Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides specialty pharmacy and key commercialization services for the bio-pharmaceutical industry through its Specialty Care Group. For more information, visit www.omnicare.com.
Forward-looking Statements
In addition to historical information, this report contains certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all statements regarding the intent, belief or current expectations regarding the matters discussed or incorporated by reference in this document (including statements as to "beliefs," "expectations," "anticipations," "intentions" or similar words) and all statements which are not statements of historical fact. Such forward-looking statements, together with other statements that are not historical, are based on management's current expectations and involve known and unknown risks, uncertainties, contingencies and other factors that could cause results, performance or achievements to differ materially from those stated. The most significant of these risks and uncertainties are described in the Company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: overall economic, financial, political and business conditions; trends in the long-term healthcare and pharmaceutical industries; the ability to attract new clients and service contracts and retain existing clients and service contracts; the ability to consummate pending acquisitions on favorable terms or at all; trends for the continued growth of the Company's businesses; trends in drug pricing; delays and reductions in reimbursement by the government and other payors to customers and to the Company; the overall financial condition of the Company's customers and the ability of the Company to assess and react to such financial condition; the ability of vendors and business partners to continue to provide products and services to the Company; the successful integration of acquired companies and realization of contemplated synergies; the continued availability of suitable acquisition candidates; the ability to attract and retain needed management; competition for qualified staff in the healthcare industry; variations in demand for the Company's products and services; variations in costs or expenses; the ability to implement productivity, consolidation and cost reduction efforts and to realize anticipated benefits; the potential impact of legislation, government regulations, and other government action and/or executive orders, including those relating to Medicare Part D, including its implementing regulations and any subregulatory guidance; reimbursement and drug pricing policies and changes in the interpretation and application of such policies, including changes in calculation of average wholesale price; discontinuation of reporting average wholesale price, and/or implementation of new pricing benchmarks; legislative and regulatory changes impacting long term care pharmacies or specialty pharmacies; government budgetary pressures and shifting priorities; federal and state budget shortfalls; efforts by payors to control costs; changes to or termination of the Company's contracts with pharmaceutical benefit managers, Medicare Part D Plan sponsors and/or commercial health insurers or to the proportion of the Company's business covered by specific contracts; the outcome of disputes and litigation; potential liability for losses not covered by, or in excess of, insurance; the impact of executive separations; the impact of benefit plan terminations; the impact of differences in actuarial assumptions and estimates as compared to eventual outcomes; events or circumstances which result in an impairment of assets, including but not limited to, goodwill and identifiable intangible assets; the final outcome of divestiture activities; market conditions; the outcome of audit, compliance, administrative, regulatory, or investigatory reviews; volatility in the market for the Company's stock and in the financial markets generally; access to adequate capital and financing; changes in our credit ratings given by rating agencies; timing of conversions of our convertible debt; changes in tax laws and regulations; changes in accounting rules and standards; the impacts of potential cybersecurity risks and/or incidents; costs to comply with the Company's Corporate Integrity Agreement; and unexpected costs and interruptions from the implementation of our new information technology system. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, the Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact:
Patrick C. Lee
+1-513-719-1507
patrick.lee@omnicare.com
Full release: http://bit.ly/1rM4Qhs
###
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire
Topic: Earnings
Source: Omnicare
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
